Back to top

Aggressive Growth

Osiris Therapeutics, Inc. (OSIR - Analyst Report) has analysts buzzing over the prospects for the next couple of years. Estimates are surging after the third consecutive earnings surprise.

But is that enough of a reason to jump into this biotech company, which also carries a Zacks #1 Rank (Strong Buy)?

Company Description

Osiris Therapeutics is a stem cell company that develops products to treat inflammatory, autoimmune, orthopedic and cardiovascular conditions. The company has commercial rights to 2 drugs in the U.S. and Canada, with the rest of the globe belonging to its strategic partner Genzyme.

Better Than Expected

On Nov 5 Osiris Therapeutics said it earned $4.5 million in the third quarter, up from a $6.8 million loss. Revenues were up marginally to $10.8 from $10.6 million, primarily due to licensing fees.

Earnings per share came in at 14 cents, a dime higher than the Zacks Consensus Estimate. Osiris Therapeutics also has about $77 million in cash and receivables.

Potential Home Run

Investors looking at companies in this or similar fields are often at the mercy of regulatory agencies. Osiris Therapeutics is no exception. But in the most recent quarter the CEO commented on the progress towards getting the world's first stem cell therapy.

However, it should be noted he did not give a timeline. Also, Osiris Therapeutics is particularly risky, given that the company's primary drug, Prochymal, has failed to pass Phase III studies twice now.

But Analysts are Optimistic

The Zacks Consensus Estimate for this year and next year popped on the earnings release. Forecasts for this year are up 22 cents, to 36 cents.

Projections for 2011 are up 43 cents, to 44 cents. Osiris Therapeutics lost 72 cents per share last year, so this is quite a turn around.

Earnings History

Osiris Therapeutics has topped forecasts in the past 3 quarters after falling short 9 consecutive times. Could this be the a sign that the company is turning the corner?

Osiris Therapeutics, Inc. - ticker OSIR >
<P ALIGN=

Bill Wilton is the Aggressive Growth Stock Strategist for Zacks.com. He is also the Editor in charge of the market-beating Zacks Small Cap Trader service

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UTD THERAPE… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%
STRATTEC SE… STRT 80.24 +3.00%